Printer Friendly

IMMUNOMEDICS AMENDS INVESTOR WARRANT AGREEMENT

 IMMUNOMEDICS AMENDS INVESTOR WARRANT AGREEMENT
 MORRIS PLAINS, N.J., June 19 /PRNewswire/ -- Immunomedics, Inc.


(NASDAQ: IMMU) announced that it has signed an amendment (the "Amendment Agreement") to a September 1988 warrant agreement. The warrant agreement, issued to a Japanese investor (the "Investor") in connection with a September 1988 private placement of the company's common stock, included a warrant to purchase up to 750,000 shares of the company's common stock on or before Sept. 22, 1992 at an exercise price of $15 per share. As a result of the March 1991 sale of convertible preferred stock and the July 1991 and January 1992 public offerings of common stock, the $15 per share exercise price of the warrant was subject to adjustment under the terms of the warrant agreement.
 Pursuant to the amendment agreement, the parties have agreed to adjust the exercise price to $12 per common share providing that, on the date of exercise, the market price of the company's common stock is not less than $7.87 nor greater than $15.87. If the market price, on the date of exercise, is less than $7.87, the exercise price for each share will be $1 less than such market price. If the market price, on the date of exercise, is greater than $15.87, the purchase price for each share will be equal to $12 plus one-half of the amount by which such market price exceeds $15.87. The warrant expires on Sept. 22, 1992, subject to extension under certain circumstances. The investor has certain piggy-back registration rights. Immunomedics currently has 28.1 million shares outstanding.
 Immunomedics is a biopharmaceutical company applying innovative technology in antibody selection, modification and chemistry to the development of products for the detection and treatment of cancers and infectious diseases. Integral to these products are highly specific monoclonal antibodies designed to deliver radioisotopes, chemotherapeutic agents or toxins to tumors and sites of infections or other diseases.
 -0- 6/19/92
 /CONTACT: Amy Factor of Immunomedics, 201-605-8200/
 (IMMU) CO: Immunomedics, Inc. ST: New Jersey IN: MTC SU:


LR-OS -- NY054 -- 1998 06/19/92 14:50 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 19, 1992
Words:351
Previous Article:STEMPEL RE-ELECTED CHAIRMAN OF MOTOR VEHICLE MANUFACTURERS ASSOCIATION; OTHER OFFICERS AND DIRECTORS ELECTED
Next Article:MAJOR DISTRIBUTION CONTRACT
Topics:


Related Articles
IMMUNOMEDICS COMPLETES OFFERING OF 2 MILLION SHARES OF COMMON STOCK COMPANY EXPANDS FACILITIES
IMMUNOMEDICS AND MALLINCKRODT SIGN U.S. MARKETING AND DISTRIBUTION AGREEMENT FOR CEA-SCAN
IMMUNOMEDICS COMPLETES $10 MILLION FINANCING
Immunomedics Commences Arbitration Proceeding Against Pharmacia & Upjohn
Immunomedics Partners with Eli Lilly for Product Distribution in Europe; LeukoScan(R) Product to be Distributed First by Lilly
Immunomedics Structures $30 Million Flexible Equity Line Financing
LA JOLLA REPORTS $66 MILLION PRIVATE PLACEMENT.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters